ArticleCureus2025
High Resolution Ultrasound for the Assessment of Melasma: Experience With 1064 nm Q-Switched Nd:YAG Laser.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melasma is a challenging chronic pigmentary disorder that holds considerable significance for both patients and dermatologists. Monitoring therapeutic outcomes is essential for optimizing treatment strategies. This study aimed to apply high-resolution dermatologic ultrasound (HRDU) to evaluate skin changes in melasma patients and document the effects observed following the application of collimated and fractional forms of 1064 nm Q-switched Nd:YAG (QSNY) laser therapy. In a prospective case series conducted from December 2024 to February 2025 at a private dermatology clinic, three patients with melasma who were indicated for QSNY laser treatment were enrolled. Each patient underwent three high-resolution dermatologic ultrasound examinations: the first before initiating QSNY laser therapy, the second 24-48 hours after the initial session, and the third three weeks following the third session. Demographic data of the sample, Melasma Severity Index (MSI) score, ultrasound grayscale, and color Doppler features were recorded and analyzed. At baseline, all patients demonstrated a subepidermal low-echogenic band (SLEB), follicular dilation, and increased vascularization in the forehead and/or cheek regions. Following the laser sessions, we observed a decrease in the SLEB, an improvement in echogenicity, and an increase in dermal capillarity. These findings provide innovative documentation of skin changes in melasma, including subclinical inflammation and solar elastosis, and highlight the potential of low fluence, fractionated QSNY laser to reduce them. HRDU emerges as a valuable tool to confirm and monitor these therapeutic benefits, supporting its role in personalized treatment strategies for melasma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.